Sanara MedTech (SMTI) AI Stock Analysis

• Market Cap: $186.22M
• Dividend Yield: N/A
• Average Volume (3M): 61.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: 30.55%
• EPS Growth: -340.19%
• Country: US
• Employees: 141
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -3.40
• Shares Outstanding: 8,935,657
• 10 Day Avg. Volume: 48,775
• 30 Day Avg. Volume: 61,645
• PEG Ratio: -0.24
• Price to Book (P/B): 7.15
• Price to Sales (P/S): 3.25
• P/FCF Ratio: -1.11K
• Enterprise Value/Market Cap: 1.14
• Enterprise Value/Revenue: 2.08
• Enterprise Value/Gross Profit: 2.26
• Enterprise Value/Ebitda: -7.92
• 1Y Price Target: $36.00
• Price Target Upside: 21.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.48
• Revenue Forecast (FY): $116.85M

• Rating: 42 Neutral
• Price Target: $21.00 ▼(-28.86% Downside)
• Action: Reiterated Date: 12/13/25
• Date: Action: Reiterated 12/13/25

Sanara MedTech's overall score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. While the earnings call showed some positive growth, technical indicators suggest a bearish trend, and valuation metrics are weak due to ongoing losses.

Positive Factors

Sustained revenue growth

Consistent, double-digit revenue growth reflects durable demand for core surgical and soft-tissue repair products. This trend supports scaling of the commercial organization and provides a multi-month runway to improve unit economics and reinvest in product adoption and distributor expansion.

Very high gross margins

A gross margin above 90% indicates strong product-level economics and pricing power versus cost of goods sold. High gross margins provide structural flexibility to fund R&D, sales expansion, or absorb SG&A increases while still having a clear path to sustainable operating profit if overhead is controlled.

Expanded commercial reach and clinical evidence

Broader distributor coverage and peer-reviewed clinical publications strengthen market access and adoption barriers. Combined with partnership progress (OsStic), this builds durable channels and clinical validation that support steady revenue capture across hospitals and specialty practices over the medium term.

Negative Factors

Weak cash generation

Persistent negative free cash flow and poor conversion of earnings into cash constrain the company’s ability to self-fund growth, R&D, and debt servicing. Over several months this increases reliance on external financing and limits strategic optionality if cash needs rise or capital markets tighten.

Rising financial leverage

Elevated and rising leverage increases interest and covenant risk, reducing financial flexibility. Given negative profitability and weak cash flow conversion, higher debt magnifies refinancing and servicing risk over the medium term and can constrain investments or force dilutive capital raises.

Product discontinuation and associated cash hit

Shutting THP after failing to monetize it is a structural setback: it reduces product diversification, requires a multi-million dollar cash outlay, and signals execution challenges in commercializing certain assets. The move impairs near-term growth optionality and diverts resources from core programs.

Sanara MedTech Business Overview & Revenue Model

Company Description

Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.

How the Company Makes Money

Sanara MedTech generates revenue primarily through the sale of its advanced wound care products to hospitals, clinics, and healthcare providers. The company employs a direct sales force as well as distribution agreements to reach its customers. Key revenue streams include product sales, licensing agreements for its proprietary technologies, and potential royalties from partnerships with other medical technology firms. Significant partnerships with healthcare organizations and distribution networks enhance its market reach and contribute to its earnings by expanding its product offerings and ensuring wide availability in various healthcare settings.

Sanara MedTech Financial Statement Overview

Summary

Sanara MedTech shows revenue growth but struggles with profitability and cash flow management. High operating expenses and increasing debt levels pose financial risks, despite a strong gross profit margin.

Income Statement

Sanara MedTech shows a consistent increase in revenue, with a TTM revenue growth rate of 4.79%. However, the company struggles with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin remains strong at over 90%, suggesting effective cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's debt-to-equity ratio has increased to 1.28 in the TTM period, indicating a higher reliance on debt financing. Return on equity is negative, reflecting ongoing losses. The equity ratio has decreased, suggesting a lower proportion of equity financing relative to total assets, which could pose risks if financial conditions worsen.

Cash Flow

Sanara MedTech's cash flow position is concerning, with negative free cash flow and a significant decline in free cash flow growth. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is positive but minimal, suggesting limited cash generation relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	101.90M	86.67M	64.99M	45.84M	24.14M	15.59M
Gross Profit	94.01M	78.53M	57.14M	39.48M	21.83M	13.97M
EBITDA	-26.79M	-1.86M	-289.10K	-11.57M	-7.22M	-4.14M
Net Income	-37.49M	-9.66M	-4.30M	-7.94M	-7.92M	-4.36M
Balance Sheet
Total Assets	71.09M	88.09M	73.87M	61.04M	36.40M	9.83M
Cash, Cash Equivalents and Short-Term Investments	14.94M	15.88M	5.15M	8.96M	18.65M	455.37K
Total Debt	47.39M	32.29M	11.79M	819.22K	425.44K	481.38K
Total Liabilities	64.95M	49.18M	29.28M	19.32M	6.24M	3.99M
Stockholders Equity	6.14M	39.40M	44.83M	41.83M	30.64M	6.15M
Cash Flow
Free Cash Flow	-865.50K	-253.08K	-3.51M	-6.30M	-5.56M	-5.68M
Operating Cash Flow	3.77M	-23.78K	-3.25M	-5.55M	-4.81M	-4.03M
Investing Cash Flow	-12.66M	-6.61M	-10.21M	-3.51M	-5.28M	-2.74M
Financing Cash Flow	7.55M	17.37M	9.64M	-627.35K	28.30M	622.33K

Sanara MedTech Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 29.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMTI, the sentiment is Neutral. The current price of 29.52 is above the 20-day moving average (MA) of 20.07, above the 50-day MA of 21.99, and above the 200-day MA of 26.87, indicating a neutral trend. The MACD of -0.33 indicates Negative momentum. The RSI at 50.78 is Neutral, neither overbought nor oversold. The STOCH value of 76.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SMTI.

Sanara MedTech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INFU	74 Outperform	$185.58M	12.68	11.54%	―	6.23%	283.88%
UTMD	71 Outperform	$213.08M	18.05	9.59%	2.15%	-12.35%	-17.20%
STXS	62 Neutral	$205.31M	-11.07	-170.24%	―	19.61%	-3.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	51 Neutral	$213.77M	-2.59	-15.30%	―	-43.95%	-620.21%
SMTI	42 Neutral	$186.22M	-2.26	-27.19%	―	30.55%	-340.19%

Sanara MedTech Corporate Events

Sanara MedTech Releases 2026 Strategy Presentation

Sanara MedTech Inc. has released an investor presentation that outlines its priorities and strategy for the 2026 fiscal year. This presentation will be used in meetings with investors and analysts, including at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025. The presentation is intended to provide context alongside the company’s SEC filings and public announcements, and it highlights the company’s strategic direction for the coming year.

The most recent analyst rating on (SMTI) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Sanara MedTech stock, see the SMTI Stock Forecast page.